Mazyar Shadman

72PUBLICATIONS

335CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersApplied statisticsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (72)

Sort by Publication Date:

|Jun 18, 2026

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

|Jun 11, 2026

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

|Jun 04, 2026

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.

|May 20, 2026

"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.

|May 14, 2026

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.

|Apr 27, 2026

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Pageof 12

Frequent Collaborators

Alex Herrera

Jordan Gauthier

Stephen D Smith

Mehdi Hamadani

Jennifer R Brown

Constantine Tam

Alexandre V Hirayama

Chaitra Ujjani

Ryan C Lynch

Mohamed A Kharfan-Dabaja

Frequent Collaborators

Alex Herrera

Jordan Gauthier

Stephen D Smith

Mehdi Hamadani